Safety, Tolerability and Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis
Multiple Sclerosis
Enrolment: 52 · Results not recorded
Loading the evidence…
Drug · Phosphodiesterase 4 inhibitor (INHIBITOR, direct interaction)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Multiple Sclerosis
Enrolment: 52 · Results not recorded
Nervous System Disease
Enrolment: 16 · Results not recorded
Huntington Disease
Enrolment: 8 · Results not recorded
Depression
Enrolment: 1 · Results not recorded
Major Depressive Disorder
Enrolment: 100 · Results not recorded
Healthy Elderly Volunteers
Enrolment: 3 · Results not recorded
Dosimetry · Healthy
Enrolment: 26 · Results not recorded
5 studies reported at therapy level; 5 evidence entries itemised.
Model: Closed head mild traumatic brain injury by standard controlled cortical impact on the left lateral hemisphere with intact skull and scalp; 2 mm diameter flat tip, 2 mm punch depth, 4.9 plus or minus 0.2 m/s velocity, 80 ms contact time, yielding neurological severity score 3 to 5 at 1 h
Endogenous cortisol rose sharply 1 h after mild TBI and was inversely correlated with circulating lymphocytes; blocking that effect with S1P or rolipram restored circulating T cells but increased inflammatory mediator expression, T cell infiltration and cell death at the impact site, indicating tha…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
Model: 60 minutes of transient middle cerebral artery occlusion (tMCAO) with reperfusion
Rolipram 10 mg/kg reduced infarct volume by 50% and improved clinical scores at day 1, preserved blood-brain barrier tight junctions, reduced oedema, inflammation, thrombosis and apoptosis, whereas 2 mg/kg had no effect.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Moderate T10 contusive spinal cord injury
Rolipram improved motor performance at every time point, reduced external foot rotation during the step cycle at 8 weeks and increased spared white matter, without altering lesion volume or length.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
Model: Moderate thoracic contusion spinal cord injury at T8 using the MASCIS impactor, 10.0 g rod dropped from 12.5 mm after laminectomy with the dura intact
Rolipram at 1.0 mg/kg once daily for two weeks preserved neurons, oligodendrocytes and central myelinated axons by the oral, subcutaneous or intravenous routes and improved Basso, Beattie and Bresnahan locomotor scores from 4 to 6 weeks, with neuronal protection retained when treatment started up t…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.
Model: Mouse spinal cord injury model (specific injury method and severity not stated in the abstract), complemented by in vitro work on activated mouse and human astrocytes and motor neurons
Nanogel-delivered rolipram was selectively internalised by activated astrocytes, limited the inflammatory response of A1 astrocytes by reducing iNOS and Lcn2, and reversed astrocyte-mediated toxicity towards motor neurons, showing an advantage over conventional administration. In the mouse spinal c…
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.